Bluebird Preamble Sample Clauses

Bluebird Preamble. Bluebird Collaboration In-License Section 4.1(b) Bluebird Development Notice Section 5.6(a) Bluebird In-Licensed IP Section 1.5 Bluebird In-License Section 1.6 Bluebird Indemnitees Section 9.6(a) Bluebird IP Section 1.5 Bluebird New In-License Section 1.6 Bluebird Option Notice Section 5.3 Bluebird Program Director Section 3.1 Business Acquisition Section 2.1(e)(ii) Business Combination 1.9 Business Party Section 2.1(e)(ii) Business Program Section 2.1(e)(ii) CAR Section 1.10
View Source
Bluebird Preamble. Bluebird In-Licensed IP Section 1.5 Bluebird Development Cap Section 4.3(c)(i) Bluebird Indemnitees Section 16.6(a) Bluebird Licensed IP Section 1.6 Bluebird Regulatory Rights Section 1.7 Bluebird Technology Section 1.8 Budgeted U.S. Development Costs Section 4.3 Business Acquisition Section 10.4 Business Party Section 10.4 Business Program Section 10.4 CCPS Agreement Preamble CCPS Agreement Effective Date Preamble CCPS Agreement Term Section 17.1 Celgene Preamble Celgene Corp Preamble Celgene Europe Preamble Celgene Indemnitees Section 16.6(b) Celgene Licensed IP Section 1.9 Celgene Licensed Product In-License Section 1.10 Celgene Licensed Product In-Licensed IP Section 1.11 Celgene Other In-License Section 1.13 Celgene Regulatory Rights Section 1.14 Celgene Technology Section 1.15
View Source
Bluebird Preamble. Bluebird In-Licensed IP Section 1.5 Bluebird Indemnitees Section 16.7(a) Bluebird Licensed IP Section 1.6 Bluebird Regulatory Rights Section 1.7 Bluebird Technology Section 1.8 Budgeted U.S. Development Costs Section 4.3 Business Acquisition Section 10.4 CONFIDENTIAL TREATMENT REQUESTED BY BLUEBIRD BIO, INC. [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES ACT OF 1934, AS AMENDED Defined Terms Location Business Party Section 10.4 Business Program Section 10.4 CCPS Agreement Preamble CCPS Agreement Effective Date Preamble CCPS Agreement Term Section 17.1 Celgene Preamble Celgene Corp Preamble Celgene Europe Preamble Celgene Indemnitees Section 16.7(b) Celgene Licensed IP Section 1.9 Celgene Licensed Product In-License Section 1.11 Celgene Licensed Product In-Licensed IP Section 1.12 Celgene Other In-License Section 1.14 Celgene Regulatory Rights Section 1.15 Celgene Technology Section 1.16 Clinical Study Section 1.17 Co-Co In Licenses Section 8.1 Combination Product Section 1.36 Commercialization Section 1.18 Commercially Reasonable Efforts Section 1.19 Competitive Infringement Section 14.1 Control Section 1.20 Cost of Goods Sold or COGS Appendix F Covers Section 1.21 Development & U.S. Commercialization Program Section 8.3(a) Distribution Costs Appendix F Elected Candidate Appendix A EU Section 1.23 EU Regulatory Event Section 1.24 Field Section 1.25 First Commercial Sale Section 1.26 First Indication Section 1.27 Fully Burdened Manufacturing Cost Appendix I GAAP Section 1.28 Gene Editing Section 1.31 Gross Profit Appendix F Gross Sales Appendix F In-License Payment Section 1.32 CONFIDENTIAL TREATMENT REQUESTED BY BLUEBIRD BIO, INC. [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES ACT OF 1934, AS AMENDED Defined Terms Location Indemnification Claim Notice Section 16.7(c) Indemnified Party Section 16.7(c) Information Request Section 5.6(g) JGC Section 3.1(a) Joint IP Section 12.2 Licensed IP Section 1.33 Licensed Product Section 1.34 Losses Section 16.7(a) Major EU Countries Section 1.24 Manufacturing Section 1.35 Manufacturing and Supply Agreement Section 7.4(b)(ii) Marke...
View Source

Related to Bluebird Preamble

  • Buyer Preamble Buyer Affiliated Group - Section 6.1(a)(i) Buyer Group - Preamble Buyer Indemnified Parties - Section 7.1(a) Claim - Section 7.3(a) Closing - Section 2.1 Closing Date - Section 2.1 Cohl - Preamble Cohl Relationship Goodwill - Section 6.1(b)(i) Cohl Services Agreement - Section 1.2 Companies - Preamble Content 2005 - Preamble Content 2006 - Preamble Contesting Party - Section 2.3(b) CPI Companies - Recital 3 CPI Intellectual Property - Section 3.1(i) CPI Permits - Section 3.1(f)(iii) Damages - Section 7.1(a) Debt - Section 3.1(d)(ii) Disclosed Liabilities - Section 3.1(d)(i) Dispute - Section 8.11 Disputing Parties - Section 8.11 Dividend Disputing Parties - Section 2.3(c) Entertainment Agreements - Section 3.1(b)(iii) Entertainment Events - Section 3.1(b)(iii) Entertainment Investments - Section 3.1(b)(iii) Equity Interests - Section 3.1(b)(iv) Existing Live Nation Equity Interests - Recitals Grand - Preamble Grand ROW - Preamble Grand Seller - Premable Indemnified Party - Section 7.3(a) Indemnifying Party - Section 7.3(a) KSC - Section 1.2 LN SEC Documents - Section 3.2(f) Lockup Agreement - Section 3.3(e) Majority Sellers - Preamble Material Contracts - Section 3.1(f)(i) Minor Contracts - Section 3.1(f)(i) Minority Seller Shares - Section 2.2(a) Minority Sellers - Preamble Non-Compete Covenant - Section 6.1(b) Non-Contesting Party - Section 2.3(b) Notice of Disagreement - Section 2.3(c) Parties - Preamble Permitted Dividends Statement - Section 2.3(b) Purchased Interests - Section 1.1 Real Estate - Section 3.1(f)(ii) Real Estate Leases - Section 3.1(f)(ii)

  • Agreement Preamble Alliance Manager 3.1 Anti-Corruption Laws 12.7(a)(i) Audited Party 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Supply Agreement 7.3(c) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) Ex-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 [*** ***] Post-Approval Commitments 6.7(b) PPQ 7.4(a) Product Infringement 14.4(a) Product Marks 14.9(a) Public Official 12.7(d) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Party 1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Request Period 2.8 Review Period 11.1(b) Royalty Floor 9.6(c)(iii) Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.79 Zymeworks Publication 11.1(c)

  • PREAMBLE The parties agree that this article constitutes the method and procedure for a final and conclusive settlement of any dispute (hereinafter referred to as "the grievance") respecting the interpretation, application, operation or alleged violation of this Collective Agreement, including a question as to whether a matter is arbitrable.

  • MODEL PREAMBLES The tenderer is referred to the "Model Preambles for Trades 2008" for supplementary and comprehensive expansion of descriptions, appropriate provision for which shall be deemed to have been included in all relevant rates Proprietary products shall be used as specified. Substitute products of similar quality and specification may only be used with prior approval by the Principal Agent. The material to be excavated is assumed to be predominantly of a composition that will allow excavation in "earth" as specified, but including a percentage of excavation in "soft rock" and "hard rock". Descriptions of carting away of excavated material shall be deemed to include loading excavated material onto trucks directly from the excavations, or alternatively, from stock piles situated on the building site.

  • PREAMBLES The preambles to this Agreement are a part of the agreement of the parties as set forth in this Agreement and shall be binding upon the parties in accordance with their terms.